Why the study?
Does sustained-release procainamide have comparable bioavailability at steady state to immediate-release procainamide in cardiac patients?
Does sustained-release procainamide have comparable bioavailability at steady state to immediate-release procainamide in cardiac patients?
This study aims to compare the steady-state bioavailability of sustained-release versus immediate-release procainamide in cardiac patients.
Comparison informs procainamide dosing in cardiac patients; leaves open whether sustained-release matches immediate-release bioavailability at steady state.
PROCAINAMIDE is effective in the prevention or treat-ment of various cardiac arrhythmias. Maintaining serum procainamide concentrations in the therapeutic range has been identified as an important factor in preventing the recurrence of cardiac arrest independent of suppression of ventricular ectopic activity ( l). Because of its relative-ly short serum half-life, procainamide usually must be administered every 3 to 4 hours, at great inconvenience to the patient, in order to maintain effective serum con-centrations and prevent excessive fluctuations above or below the therapeutic range (2). A recently marketed, sustained-release dosage form of procainamide, Procan-SR (Parke-Davis, Morris Plains, New Jersey), has been found to be bioequivalent to immediate-release procain-amide capsules in normal volunteers (3). We compared
No takes yet. Share an insight, caveat, or question.
Peter H. Vlasses (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: